Patent classifications
C07D515/04
Heterocyclic compounds as immunomodulators
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. ##STR00001##
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
- Jason McCartney ,
- Alexander Russell Abela ,
- Sunny Abraham ,
- Corey Don ANDERSON ,
- Vijayalaksmi Arumugam ,
- Jaclyn CHAU ,
- Jeremy CLEMENS ,
- Thomas Cleveland ,
- Timothy Richard Coon ,
- Andrew DINH ,
- Timothy A. DWIGHT ,
- Lev Tyler Dewey Fanning ,
- Bryan A. Frieman ,
- Peter Grootenhuis ,
- Sara Sabina Hadida Ruah ,
- Yoshihiro ISHIHARA ,
- Paul KRENITSKY ,
- Mark Thomas MILLER ,
- Fabrice Pierre ,
- Alina SILINA ,
- Joe A. TRAN ,
- Lino Valdez ,
- Jinglan Zhou
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
##STR00001##
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
- Jason McCartney ,
- Alexander Russell Abela ,
- Sunny Abraham ,
- Corey Don ANDERSON ,
- Vijayalaksmi Arumugam ,
- Jaclyn CHAU ,
- Jeremy CLEMENS ,
- Thomas Cleveland ,
- Timothy Richard Coon ,
- Andrew DINH ,
- Timothy A. DWIGHT ,
- Lev Tyler Dewey Fanning ,
- Bryan A. Frieman ,
- Peter Grootenhuis ,
- Sara Sabina Hadida Ruah ,
- Yoshihiro ISHIHARA ,
- Paul KRENITSKY ,
- Mark Thomas MILLER ,
- Fabrice Pierre ,
- Alina SILINA ,
- Joe A. TRAN ,
- Lino Valdez ,
- Jinglan Zhou
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
##STR00001##
NOVEL ISOTHIAZOLO-BASED BICYCLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR PLANT GROWTH REGULATORS
The invention relates to the technical field of herbicides and/or plant growth regulators. Specifically, the invention relates to novelisothiazolo-based bicycles, and compositions comprising said novelisothiazolo-based bicycles. Further, the present invention relates to processes for the preparation said novel isothiazolo-based bicycles and their use as herbicides and/or plant growth regulators.
BISARYL HETEROCYCLES AS NRF2 ACTIVATORS
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I),
##STR00001##
BISARYL HETEROCYCLES AS NRF2 ACTIVATORS
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I),
##STR00001##
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF
Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.
HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF
Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.